{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:35:43Z","timestamp":1788305743078,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001297","name":"Royal College of Anaesthetists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012373","name":"National Institute of Academic Anaesthesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011716","name":"British Journal of Anaesthesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bja.2025.10.047","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T21:26:43Z","timestamp":1764278803000},"page":"600-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-7839","authenticated-orcid":false,"given":"Mia E.","family":"Koponen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-4632","authenticated-orcid":false,"given":"Dhaneesha N.S.","family":"Senaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5362-9430","authenticated-orcid":false,"given":"Blair H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2025.10.047_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","article-title":"Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)","volume":"114","author":"Bouhassira","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.bja.2025.10.047_bib3","article-title":"Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank","volume":"8","author":"Baskozos","year":"2023","journal-title":"Pain Rep"},{"key":"10.1016\/j.bja.2025.10.047_bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"van Hecke","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3111\/13696998.2012.729548","article-title":"The burden associated with neuropathic pain in Western Europe","volume":"16","author":"Langley","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.bja.2025.10.047_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bja.2025.10.047_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bja.2025.10.047_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/j.pain.0000000000001439","article-title":"Longitudinal pattern of pain medication utilization in peripheral neuropathy patients","volume":"160","author":"Callaghan","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib9","doi-asserted-by":"crossref","first-page":"e1415","DOI":"10.1212\/WNL.0000000000009039","article-title":"Association of out-of-pocket costs on adherence to common neurologic medications","volume":"94","author":"Reynolds","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bja.2025.10.047_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fphar.2018.01540","article-title":"Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug adherence","volume":"9","author":"Burnier","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bja.2025.10.047_bib11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/pme.12095","article-title":"Pharmacological treatment patterns in neuropathic pain\u2014lessons from Swedish administrative registries","volume":"14","author":"Gustavsson","year":"2013","journal-title":"Pain Med"},{"key":"10.1016\/j.bja.2025.10.047_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.pain.2012.01.015","article-title":"Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations?","volume":"153","author":"Dworkin","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/pme.12845","article-title":"Suboptimal treatment of diabetic peripheral neuropathic pain in the United States","volume":"16","author":"Yang","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.bja.2025.10.047_bib14","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2025.10.047_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002\u20132005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/POR.S49746","article-title":"Incidence of diabetic peripheral neuropathic pain in primary care \u2013 a retrospective cohort study using the United Kingdom General Practice Research Database","volume":"4","author":"Reed","year":"2013","journal-title":"Pragmatic Obs Res"},{"key":"10.1016\/j.bja.2025.10.047_bib18","first-page":"299","article-title":"Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain","volume":"7","author":"Sicras-Mainar","year":"2015","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.bja.2025.10.047_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"10.1016\/j.bja.2025.10.047_bib20","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2025.10.047_bib21","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2025.10.047_bib22","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.2147\/JPR.S493542","article-title":"Prescribing patterns and off-label use of gabapentinoid agents at Dhulikhel Hospital, Nepal: a cross-sectional study","volume":"17","author":"Adhikari","year":"2024","journal-title":"J Pain Res"},{"key":"10.1016\/j.bja.2025.10.047_bib23","article-title":"Drug Usability Survey (DUS) of gabapentinoid and its combinations among Indian patients with neuropathic pain: results from a real-world, multicenter, retrospective survey at neurology clinics","volume":"17","author":"Aggarwal","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.bja.2025.10.047_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pcd.2013.08.004","article-title":"Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in type 1 diabetes","volume":"8","author":"Anderson","year":"2014","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.bja.2025.10.047_bib25","first-page":"423","article-title":"Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in people with type 2 diabetes","volume":"20","author":"Anderson","year":"2016","journal-title":"J Diabetes Nurs"},{"key":"10.1016\/j.bja.2025.10.047_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/15360288.2023.2174635","article-title":"Characterization of outpatient gabapentinoid prescribing for pain","volume":"37","author":"Banks","year":"2023","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.bja.2025.10.047_bib27","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/S0149-2918(03)80335-1","article-title":"Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia","volume":"25","author":"Berger","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.bja.2025.10.047_bib28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1185\/03007990902997309","article-title":"Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain","volume":"25","author":"Boulanger","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bja.2025.10.047_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/sjpain-2018-0317","article-title":"The utility\/futility of medications for neuropathic pain \u2013 an observational study","volume":"19","author":"Butler","year":"2019","journal-title":"Scand J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s41983-021-00398-x","article-title":"Dispensing patterns of drugs used for neuropathic pain and adherence to NeuPSIG guideline: an observational study","volume":"57","author":"Chahine","year":"2021","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"10.1016\/j.bja.2025.10.047_bib31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1185\/03007995.2010.518438","article-title":"Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments","volume":"26","author":"Chen","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bja.2025.10.047_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1533-2500.2010.00372.x","article-title":"The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy: duloxetine average daily dose, adherence and costs","volume":"10","author":"Chen","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3111\/13696998.2011.585676","article-title":"Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study","volume":"14","author":"Chen","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.bja.2025.10.047_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.pain.2008.03.002","article-title":"Incidence rates and treatment of neuropathic pain conditions in the general population","volume":"137","author":"Dieleman","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib35","first-page":"940","article-title":"Drug utilization patterns for peripheral neuropathy in a neurology outpatient department at a tertiary care center: a cross-sectional observational study","volume":"14","author":"Dinesh Babu","year":"2024","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.bja.2025.10.047_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/15360288.2020.1784354","article-title":"Comparing effectiveness of gabapentin and pregabalin in treatment of neuropathic pain: a retrospective cohort of palliative care outpatients","volume":"34","author":"Dragic","year":"2020","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.bja.2025.10.047_bib37","first-page":"2553","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data","volume":"28","author":"Gewandter","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bja.2025.10.047_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/AJP.0b013e31825e45d9","article-title":"Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy","volume":"29","author":"Gharibian","year":"2013","journal-title":"Clin J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/AJP.0b013e31802fc14a","article-title":"Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy","volume":"23","author":"Giannopoulos","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ejpain.2006.10.004","article-title":"Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings","volume":"11","author":"Gore","year":"2007","journal-title":"Eur J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib41","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.clinthera.2007.08.019","article-title":"A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings","volume":"29","author":"Gore","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.bja.2025.10.047_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1533-2500.2010.00415.x","article-title":"Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care","volume":"11","author":"Gore","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1533-2500.2011.00450.x","article-title":"Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin","volume":"11","author":"Gore","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib44","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/08971900221087119","article-title":"Gabapentin and opioids utilization in patients with diabetic neuropathy enrolled in Medicare (2012\u20132016): a cohort study","volume":"36","author":"Goswami","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pain.2006.01.030","article-title":"Epidemiology and treatment of neuropathic pain: the UK primary care perspective","volume":"122","author":"Hall","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib46","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/healthcare11050764","article-title":"Patterns and trends in pharmacological treatment for outpatients with postherpetic neuralgia in six major areas of China, 2015\u20132019","volume":"11","author":"Han","year":"2023","journal-title":"Healthcare"},{"key":"10.1016\/j.bja.2025.10.047_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.pcd.2020.12.005","article-title":"Incidence of antiepileptic drug therapy and factors associated with their prescribing in outpatients with diabetic polyneuropathy","volume":"15","author":"Jacob","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.bja.2025.10.047_bib48","first-page":"488","article-title":"An observational study on effectiveness and safety of amitriptyline, duloxetine, and pregabalin in painful diabetic neuropathy","volume":"16","author":"Jha","year":"2024","journal-title":"Int J Pharm Clin Res"},{"key":"10.1016\/j.bja.2025.10.047_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40261-012-0030-4","article-title":"Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin","volume":"33","author":"Johnson","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bja.2025.10.047_bib50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/pme.12328","article-title":"Characteristics, treatment, and health care expenditures of Medicare supplemental-insured patients with painful diabetic peripheral neuropathy, post-herpetic neuralgia, or fibromyalgia","volume":"15","author":"Johnston","year":"2014","journal-title":"Pain Med"},{"key":"10.1016\/j.bja.2025.10.047_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14656566.2022.2155048","article-title":"Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study","volume":"24","author":"Kato","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bja.2025.10.047_bib52","first-page":"445","article-title":"Exploring analgesic use patterns among cancer survivors with chronic chemotherapy-induced peripheral neuropathy","volume":"51","author":"Knoerl","year":"2024","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.bja.2025.10.047_bib53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jpain.2009.07.001","article-title":"Pharmacological treatment of neuropathic facial pain in the Dutch general population","volume":"11","author":"Koopman","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/15360288.2016.1210713","article-title":"Single- versus multiple-drug pharmacotherapy in the management of diabetic painful neuropathy","volume":"30","author":"Kuo","year":"2016","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.bja.2025.10.047_bib55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clbc.2023.05.002","article-title":"Factors associated with guideline-concordant pharmacological treatment for neuropathic pain among breast cancer survivors","volume":"23","author":"Lakkad","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bja.2025.10.047_bib56","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.jpain.2023.07.011","article-title":"Prescription opioid initiation for neuropathy, headache, and low back pain: a US population-based Medicare study","volume":"24","author":"Lin","year":"2023","journal-title":"J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib57","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.3390\/jcm13195682","article-title":"Assessing gender differences in neuropathic pain management: findings from a real-life clinical cross-sectional observational study","volume":"13","author":"Marcian\u00f2","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.bja.2025.10.047_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/JPR.S118248","article-title":"Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims","volume":"10","author":"Margolis","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.bja.2025.10.047_bib59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/00207454.2011.582238","article-title":"Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy","volume":"121","author":"Mittal","year":"2011","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.bja.2025.10.047_bib60","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/j.pain.0000000000002525","article-title":"Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents","volume":"163","author":"Mbrah","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib61","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/head.14952","article-title":"Second-line pharmacological treatment strategies for trigeminal neuralgia: a retrospective comparison of lacosamide, gabapentin and baclofen","volume":"65","author":"Mu\u00f1oz-Vendrell","year":"2025","journal-title":"Headache"},{"key":"10.1016\/j.bja.2025.10.047_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12891-024-07599-4","article-title":"Current trends in the medical treatment of neuropathic low back pain: a Swedish registry-based study of 1.7 million people","volume":"25","author":"Nyqvist","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.bja.2025.10.047_bib63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.clinthera.2012.02.007","article-title":"A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid","volume":"34","author":"Oladapo","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.bja.2025.10.047_bib64","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/AJP.0000000000000124","article-title":"Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population","volume":"31","author":"Patil","year":"2015","journal-title":"Clin J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib65","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/pme.12276","article-title":"Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain","volume":"14","author":"P\u00e9rez","year":"2013","journal-title":"Pain Med"},{"key":"10.1016\/j.bja.2025.10.047_bib66","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7196\/SAMJnew.7908","article-title":"Pharmacological treatment of painful HIV-associated sensory neuropathy","volume":"105","author":"Pillay","year":"2015","journal-title":"S Afr Med J"},{"key":"10.1016\/j.bja.2025.10.047_bib67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mus.26774","article-title":"Randomized controlled trial of a clinical decision support system for painful polyneuropathy","volume":"61","author":"Reynolds","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bja.2025.10.047_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DMSO.S37415","article-title":"Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey","volume":"6","author":"Sadosky","year":"2013","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.bja.2025.10.047_bib69","first-page":"158","article-title":"Therapeutic and subtherapeutic dosing of pregabalin: medication adherence, healthcare resource utilization, and costs","volume":"4","author":"Sanchez","year":"2012","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.bja.2025.10.047_bib70","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/AJP.0000000000000206","article-title":"Relationships among adverse events, disease characteristics, and demographics in treatment of postherpetic neuralgia with gastroretentive gabapentin","volume":"31","author":"Shaparin","year":"2015","journal-title":"Clin J Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737167.2019.1519399","article-title":"Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin","volume":"19","author":"Sicras-Mainar","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.bja.2025.10.047_bib72","doi-asserted-by":"crossref","first-page":"516","DOI":"10.15562\/bmj.v7i2.1070","article-title":"Medicine reminder to improve treatment compliance on geriatric patients with diabetic neuropathy at Sanglah Central Hospital, Bali-Indonesia","volume":"7","author":"Sutema","year":"2018","journal-title":"Bali Med J"},{"key":"10.1016\/j.bja.2025.10.047_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/JPR.S56883","article-title":"The importance of catastrophizing for successful pharmacological treatment of peripheral neuropathic pain","volume":"7","author":"Toth","year":"2014","journal-title":"J Pain Res"},{"key":"10.1016\/j.bja.2025.10.047_bib74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/JPR.S160504","article-title":"Epidemiology of physician-diagnosed neuropathic pain in Brazil","volume":"12","author":"Udall","year":"2019","journal-title":"J Pain Res"},{"key":"10.1016\/j.bja.2025.10.047_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10194-020-01123-4","article-title":"Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study","volume":"21","author":"Wang","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib76","first-page":"61","article-title":"Impact of a Clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain","volume":"12","author":"Winterbottom","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.bja.2025.10.047_bib77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3111\/13696990903240559","article-title":"Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain","volume":"12","author":"Wu","year":"2009","journal-title":"J Med Econ"},{"key":"10.1016\/j.bja.2025.10.047_bib78","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1533-2500.2010.00392.x","article-title":"Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies","volume":"11","author":"Wu","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242467","article-title":"Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: a MarketScan database study","volume":"16","author":"Yeh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bja.2025.10.047_bib80","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1185\/03007995.2011.554807","article-title":"Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin","volume":"27","author":"Zhao","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bja.2025.10.047_bib81","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1533-2500.2011.00494.x","article-title":"Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study","volume":"12","author":"Zhao","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s42466-020-00064-2","article-title":"Diagnosis of peripheral neuropathy","volume":"2","author":"Lehmann","year":"2020","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.bja.2025.10.047_bib83","first-page":"e87","article-title":"Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked survey and administrative data","volume":"5","author":"Morgan","year":"2011","journal-title":"Open Med"},{"key":"10.1016\/j.bja.2025.10.047_bib84","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00005650-200201000-00007","article-title":"Disparities in health care by race, ethnicity, and language among the insured: findings from a national sample","volume":"40","author":"Fiscella","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.bja.2025.10.047_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1077558700057001S06","article-title":"Racial and ethnic differences in access to medical care","volume":"57","author":"Mayberry","year":"2000","journal-title":"Med Care Res Rev"},{"key":"10.1016\/j.bja.2025.10.047_bib86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/j.pain.0000000000002688","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis","volume":"164","author":"Balanaser","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib87","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.pain.2013.04.015","article-title":"Natural history of herpes zoster: late follow-up of 3.9 years (n = 43) and 7.7 years (n = 10)","volume":"154","author":"Reda","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.bja.2025.10.047_bib88","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/pgmj.59.695.556","article-title":"The natural history of painful diabetic neuropathy\u2014a 4-year study","volume":"59","author":"Boulton","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bja.2025.10.047_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225007871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225007871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:44:02Z","timestamp":1779813842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091225007871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0007091225007871"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2025.10.047","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2025.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.","name":"copyright","label":"Copyright"}]}}